Diagnosis and Assessment of Takayasu Arteritis by Multiple Biomarkers

Ishihara, Takashi; Haraguchi, Go; Tezuka, Daisuke; Kamiishi, Tetsuo; Inagaki, Hiroshi; Isobe, Mitsuaki

doi:10.1253/circj.cj-12-0131

Cited by 80 publications

(67 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В качестве новых перспективных биомаркеров ак-тивности АТ обсуждаются матриксная металлопротеи-наза 9, пентраксин 3, чувствительность и специфичность которых, как показано, не зависят от использования ГК [62,63]. Острофазовый реактант пентраксин 3 продуциру-ется широким спектром клеток, включая макрофаги, ден-дритные клетки, фибробласты, клетки гладкой мускулату-ры, адипоциты, эндотелиальные клетки сосудов, нейтро-филы.…”

Section: Discussionunclassified

“…Острофазовый реактант пентраксин 3 продуциру-ется широким спектром клеток, включая макрофаги, ден-дритные клетки, фибробласты, клетки гладкой мускулату-ры, адипоциты, эндотелиальные клетки сосудов, нейтро-филы. Получены данные, что пентраксин 3 коррелирует с активностью васкулита [49,[63][64][65], в том числе с данны-ми КТ-ангиографии на фоне лечения ТЦЗ, превосходя клиническое значение СРБ и СОЭ [49,66]. Интересно, что продукция пентраксина 3 индуцируется не ИЛ6, а другими провоспалительными цитокинами, в частности ФНОα, что рассматривается как один из аргументов применения ингибиторов ФНОα при АТ [49].…”

Section: Discussionunclassified

See 1 more Smart Citation

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Бекетова¹,

Насонов²

2017

rsp

View full text Add to dashboard Cite

Section: Discussionunclassified

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Бекетова¹,

Насонов²

2017

rsp

View full text Add to dashboard Cite

“…В последние годы появились новые потенциальные биомаркеры для оценки активности АТ, такие как пентраксин-3 и матриксная металлопро-теиназа-9, обладающие более высокой чувствительно-стью по сравнению с СОЭ и СРБ. Кроме того, на их содержание в плазме крови не влияет терапия глюко-кортикоидами [14]. Предшественник пентраксина-3, обнаруженный в стенке артерии у пациентов с АТ, принимает активное участие в иммунных реакциях, поскольку является острофазовым белком.…”

Section: клиническое наблюдениеunclassified

“…Предшественник пентраксина-3, обнаруженный в стенке артерии у пациентов с АТ, принимает активное участие в иммунных реакциях, поскольку является острофазовым белком. Однако диагностическая ценность вышеуказанных показате-лей в оценке степени активности АТ требует дальней-ших исследований [14,15]. В отличие от васкулитов, поражающих сосуды мелкого и среднего диаметра, при АТ нельзя выпол-нить диагностическую биопсию крупной артерии для оценки активности заболевания [16].…”

Section: клиническое наблюдениеunclassified

Systemic Vasculitis With Lesion of Large Vessels as a Cause of Art Erial Hypert Ension in a Patient of Young Age

et al. 2018

View full text Add to dashboard Cite

Objective:to analyze and present a clinical case of late diagnosis of Takayasu’s arteritis in a young female patient with long-term arterial hypertension.Materials and methods.The female patient G., born in 1989, had noted elevated arterial pressure (AP) of 150/90 mm Hg since she was 14. At 21 the following diagnosis was stated: Fibro-muscular dysplasia, stenosis of the left renal artery. Stenosis of the celiac trunk. Aneurisms of the branches of the superior mesenteric artery; prosthesis of the left renal artery was performed. Since the beginning of 2016, the patient has noted elevated AP of 200/110 mm Hg despite continuing hypotensive therapy. Diagnosis of Nonspecific aortoarteritis was proposed in May of 2017. Methylprednisolone therapy was administered: 250 mg No. 2 intravenously, Prednisolone: 25 mg a day orally. Due to signs of decreased blood flow to the left kidney, in August of 2017 extracorporeal repeat prosthesis of the left renal artery, bypass of the right middle renal artery with reversed autovein were performed.Results.During examination in October of 2017, the patient complained of weakness, frequent elevated AP of 200/110 mm Hg. In blood test: hemoglobin 106 g/l, erythrocyte sedimentation rate 38 mm/h, C-reactive protein 25 mg/l. A heterozygous mutation in the methylenetetrahydropholate reductase, a heterozygous mutation in the factor V gene (G1691A) were identified. Homocysteine level was normal, infection and oncological pathology were excluded. The following diagnosis was made: Takayasu»s arteritis type IV affecting the aorta and its branches, moderate activity. Occlusion of the celiac trunk. Aneurisms of the branches of the superior mesenteric artery. Critical stenosis of the left renal artery. Thrombosis of the aorto-renal prosthesis. Hypoplasia of the left kidney. Prednisolone 50 mg a day, metoprolol 50 mg a day, valsartan 160 mg a day, acetylsalicylic acid 100 mg a day were prescribed.Conclusion.The presented clinical observation shows the importance of comprehensive examination of young patients complaining of elevated AP for many years. Due to untimely diagnosis and absence of pathogenetic therapy, the patient suffered negative consequences of surgical treatment.

show abstract

“…Recently, pentraxin 3 (PTX3), which is produced by immune and vascular cells in response to proinflammatory signals, was suggested as a biomarker for disease activity in patients with TAK (36)(37)(38). In a single-center study from Italy, the levels of PTX3 were higher in patients with active TAK (median: >2.14 ng/mL) than in patients with inactive TAK (0.63 ng/mL), patients with infections (0.26 ng/mL), and healthy controls (0.11 ng/mL) (35).…”

Section: Laboratory Search For a Biomarkermentioning

confidence: 99%

Recent advances in Takayasu's arteritis

Alıbaz-Öner¹,

Aydın²,

Direşkeneli³

2015

Eur J Rheumatol

View full text Add to dashboard Cite

Takayasu's arteritis (TAK) is a rare, chronic large-vessel vasculitis (LVV) that predominantly affects the aorta, its major branches, and the pulmonary arteries. Recent advances in the diagnosis, clinical course, disease assessment with biomarkers/imaging and new clinical tools, patient-reported outcomes, and new treatment options of TAK are discussed in this review. Conventional angiography, the gold standard method for initial diagnosis, appears to have been replaced with new imaging modalities such as magnetic resonance angiography (MRA) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in recent years. MRA and FDG-PET are also promising for the assessment of disease activity. New tools for disease assessment such as Indian Takayasu's Arteritis Score 2010 (ITAS2010) and color Doppler ultrasound (CDUS) aim to better characterize and quantify disease activity; however, different imaging modalities in routine follow-up are not incorporated sufficiently in these approaches. Prognosis is possibly getting better, with lower mortality in recent years; however, it is difficult to assess the widely different vascular intervention rates among the clinical series. Leflunomide, tumor necrosis factor (TNF)-α antagonists, and tocilizumab are new options for patients resistant to conventional therapies. There is a clear need to develop a validated set of outcome measures for use in clinical trials of TAK. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group has taken on this task, finished a Delphi exercise with experts, and aims to develop a core set of outcomes for LVV in accordance with OMERACT Filter 2.0.

show abstract

Diagnosis and Assessment of Takayasu Arteritis by Multiple Biomarkers

Cited by 80 publications

References 20 publications

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Innovative Treatments for Takayasu’s Arteritis: A Focus on Interleukin-6 Inhibitors. The Authors’ Experience With Tocilizumab and a Review of Literature

Systemic Vasculitis With Lesion of Large Vessels as a Cause of Art Erial Hypert Ension in a Patient of Young Age

Recent advances in Takayasu's arteritis

Contact Info

Product

Resources

About